Folgen
Keine Story von Helsinn Healthcare SA mehr verpassen.

Helsinn Healthcare SA

Filtern
  • 31.07.2006 – 11:00

    A top-gear drug for the treatment of pain and inflammation

    Lugano (ots) - New evidences confirm the assets of Original Nimesulide(1): multifactorial pharmacological activity, fast analgesic action, proven clinical efficacy Presented at Helsinn Satellite Symposium "A valuable common approach to the treatment of different pain conditions " 12th International Pain Clinic Congress 2006, World Society of Pain Clinicians Turin (Italy), 4-7 July 2006 New ...

  • 08.02.2006 – 08:00

    HELSINN and THERABEL PHARMA announce a license agreement for Aloxi®

    Lugano (ots) - HELSINN HEALTHCARE SA signed an Agreement with THERABEL PHARMA under which it granted THERABEL PHARMA the exclusive License and Distribution rights to distribute, market and sell Aloxi® (palonosetron hydrochloride) in France, Belgium, Luxemburg and The Netherlands. Aloxi® is a strong and long-lasting antiemetic belonging to ...

  • 22.06.2005 – 08:00

    Helsinn and Angelini announce a license agreement for ALOXI® in Portugal

    Lugano, Switzerland and Lisboa, Portugal (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ANGELINI FARMACÊUTICA, a Portuguese Pharmaceutical company, announce the signing of an agreement granting ANGELINI the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in PORTUGAL. ALOXI® is a strong and long acting ...

  • 13.06.2005 – 12:00

    Exelixis and Helsinn sing agreement for XL119 (Becatecarin)

    South San Francisco, Calif and Lugano, Switzerland (ots) - Exelixis, Inc. (Nasdaq: EXEL) and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition, Helsinn will assume the cost of the Phase III program going forward. In return, Exelixis ...

  • 01.06.2005 – 08:00

    Helsinn Healthcare Licenses a Supportive Care Product from Roche

    Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ROCHE today announced the signing of a licensing agreement, granting HELSINN HEALTHCARE the worldwide rights for the patented, phase II product, NETUPITANT. Netupitant is a potent and selective NK-1 receptor antagonist, developed as NKE by Roche, for the prevention of chemotherapy-induced nausea and vomiting (CINV). "We are ...

  • 30.05.2005 – 08:00

    HELSINN'S ISO 14001 and OHSAS 18001 CERTIFICATION

    Biasca, Switzerland (ots) - Helsinn Chemicals SA and Helsinn Advanced Synthesis SA have successfully passed a re-certification audit of its ISO14001 Environmental Management System. The audit by SGS took place on May 2nd and 3rd 2005. In parallel, Helsinn has also applied for an audit from SGS to inspect the Helsinn sites in relation to the Occupational Health and Safety Assessment Series (OHSAS) 18001 ...

  • 04.04.2005 – 08:00

    HELSINN new antiemetic drug ALOXI® receives marketing authorization in Europe

    Lugano Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, announced today that the European Commission has granted the marketing authorisation for their new drug ALOXI®. This announcement comes approximately three months after the CHMP's recommendation to approve ALOXI" for the prevention of acute nausea and vomiting associated with highly ...

  • 24.03.2005 – 08:46

    HELSINN AND CSC announce a license agreement for A ALOXI® in Central and Eeastern Europe

    LUGANO, SWITZERLAND, and VIENNA, AUSTRIA (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and CSC, a Pharmaceutical company based in AUSTRIA, announce the signing of an agreement granting CSC the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in Austria and other countries in Central and Eastern Europe. ALOXI® is ...